Adrenal glands metastases from malignant melanoma. Laparoscopic bilateral adrenalectomy

Journal of Experimental and Clinical Cancer Research

Volumn 22, Issue 1, 2003, Pages 141-145

  Carlini, Massimo ^a   Lonardo, M T ^a   Boschetto, A ^a   Carboni, F ^a   Appetecchia, M ^a   Tropea, F ^a   Santoro, E ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Adrenal gland; Laparoscopic adrenalectomy; Melanoma; Metastasis

Indexed keywords

ADRENAL METASTASIS; ADRENALECTOMY; AGED; ARTICLE; CANCER SURGERY; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LAPAROSCOPIC SURGERY; MALE; MELANOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADRENAL GLAND NEOPLASMS; ADRENALECTOMY; AGED; HUMANS; LAPAROSCOPY; MALE; MELANOMA; NEOPLASM METASTASIS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0037352868     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Das Gupta T., Brasfield R.: Metastatic melanoma: a clinicopathological study. Cancer 10:1323-1391, 1964.
2. Fusi S., Ariyan S., Sternlicht A.: Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast. Reconstr. Surg. 91:94-98, 1993.
3. Markowitz J.S., Cosimi L.A., Carey R.W. et al.: Prognosis after initial recurrence of cutaneous melanoma. Arch. Surg. 126:703-708, 1991.
4. Reintgen D.S., Cox C., Slingluff C.L.J., Seigler H.F.: Recurrent malignant melanoma. The identification of prognostic factors to predict survival. Ann. Plast. Surg. 28:45-49, 1992.
5. Crowley N.J., Seigler H.F.: Relationship between disease-free interval and survival in patients with recurrent melanoma. Arch. Surg. 127:1303-1308, 1992.
6. Cohn-Cedemark G., Mansson-Brahme E., Rutqvist L.E., Larsson O. et al.: Metastatic patterns, clinical outcome and malignant phenotype in malignant cutaneous melanoma. Acta Oncol. 38:1069-1074, 1999.
7. Claude R., Sale J.M., Cavillon C., Rigondet G. et al.: A' propos d'un cas de métastase surrénalienne d'un mélanome cutané traité par l'exérèse avec survie de 3 ans. Ann. Urol. 30:44-45, 1996.
8. Branum G.D., Epstein R.E., Leight G.S. and Seigler H.F.: The role of resection in the management of melanoma metastatic to the adrenal gland. Surgery 109:127-131, 1991.
9. Kirsch A.J., Oz M.C., Stoopler M., Ginsburg M. and Steinglass K.: Operative management of adrenal metastases from lung carcinoma. Urology 42:716-719, 1993.
10. Raviv G., Klein E., Yellin A., Schneebaum S., Ben-Ari G.: Surgical treatment of solitary adrenal metatases from lung carcinoma. J. Surg. Oncol. 43:123-124, 1990.
11. Sasaki Y., Imaoko S., Shibata T. et al.: Successful surgical management of pulmonary and adrenal metastases from hepatocellular carcinoma. Eur. J. Surg. Oncol. 17:84-90, 1991.
12. Fox M., Grant J.B.F., Grainger R.G.: Bilateral adrenal metastases from renal carcinoma treated surgically with prolonged survival. Br. J. Urol. 58:561-563, 1986.
13. Yeung R.S.W.: Management of recurrent cutaneous melanoma. Curr. Probl. Cancer 18:143-186, 1994.
14. McCarthy W.H., Shaw H.M., Thompson J.F., Milton G.W.: Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg. Gynecol. Obstet. 166:497-502, 1988.
15. Balch C.M.: Cutaneous melanoma: prognosis and treatment results worldwide. Sem. Surg. Oncol. 43:370-375, 1992.
16. Worth A.J., Gallagher R.P., Elwood J.M. et al.: Pathologic prognostic factors for cutaneous malignant melanoma: the Western Canada melanoma study. Int. J. Cancer 43:370-375, 1989.
17. Wahl R.L., Hutchins G.D., Buchsbaum D.J.: Fluorine-18-2-deoxy-2-fluoro-D-glucose (FDG) uptake into human tumor xenografts: feasibility studies for cancer imaging with PET. Cancer 67:1544-1549, 1991.
18. Gritters L.S., Francis I.R., Zasadny K.R. et al.: Initial assessment of positron emission tomography using 2-fluorine-18- fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J. Nucl. Med. 34:1420-1427, 1993.
19. Blessing C., Feine U., Geiger L. et al.: Positron emission tomography and ultrasonography. Arch. Dermatol. 131:1394-1398, 1995.
20. Boni R., Boni R.A.H., Steinert H. et al.: Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br. J. Dermatol. 132:556-562, 1995.
21. Steinert H.C., Boni R.A.H., Buck A. et al.: Malignant melanoma: staging with whole-body positron emission tomography and 2-(F-18)-fluoro-deoxy-D-glucose. Radiology 195:1705-1709, 1995.
22. Pounds T.R., Walk P.E., Haseman M.K. et al.: Whole-body PET-FDG imaging in diagnosis of metastatic melanoma: comparison to CT. J. Nucl. Med. 36:116P, 1995.
23. Argenyi E.E., Urdanela L.F., Whitaker D.C. et al.: Clinical utility of F- 18- FDG and PET imaging in detecting metastatic melanoma. J. Nucl. Med. 36:193P, 1995.
24. Wohrle H., Feine U., Geiger L. et al.: Whole body 18-FDG PET in 46 patients with recurrent malignant melanoma: a comparson versus CT and MRI. Eur. J. Nucl. Med. 22:753, 1995.
25. Paquet P., Hustinx R., Rigo P., Pièrard G.E.: Malignant melanoma staging using whole-body positrin emission tomography. Melanoma Res. 8:59-62, 1998.
26. Soong S.J., Harrison R.A., McCarthy W.H., Urist M.M., Balch C.M.: Factors affecting survival following local regional or distant recurrence from localized melanoma. J. Surg. Oncol. 67:228-233, 1998.
27. Buzzell R.A., Zitelli J.A.: Favorable prognostic factors in recurrent and metastatic melanoma. J. Am. Acad. Dermatol. 34:798-803, 1996.
28. Gadd M.A., Coit D.G.: Recurrence patterns and outcome in 1019 patients undergoing axillary or inguinal lymphoadenectomy for melanoma. Arch. Surg. 127:1412-1416, 1992.
29. Balch C.M., Soong S.J., Shaw H.M. et al.: Malignant melanoma - compared worldwide. Chirurg. 57:601-605, 1986.
30. Balch C.M., Soong S.J., Gershenwald J.E. et al.: Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 19:3622-3634, 2001.
31. Lo C.Y., van Herdeen J.A. Soreide J.A. et al.: Adrenalectomy for metastatic disease to the adrenal glands. Br. J. Surg. 83:528-531, 1996.
32. Kim S.H., Brennan M.F., Russo P. et al.: The role of surgery in the treatment of clinically isolated adrenal metastasis. Cancer 82:389-394, 1998.
33. De Perrot M., Licker M., Robert J.M., Spilipoulos A.: Long term survival after surgical resections of bronchogenic carcinoma and adrenal metastasis. Ann. Thor. Surg. 68:1084-1085, 1999.
34. Wade T.P., Longo W.E., Virgo K.S., Johnson F.E.: A comparison between adrenalectomy with other resections for metastatic cancers. Am. J. Surg. 175:183-186, 1998.
35. Lam K.I., Lot C.Y.: Metastatic tumours of the adrenal glands: a 30-year-experience in a teaching hospital. Clin. Endocrinol. 56:95-101, 2002.
36. Haigh P.I., Essner R., Wardlaw J. et al.: Long-term survival after complete resection of melanoma metastatic to the adrenal gland. Ann. Surg. Oncol. 6:633-639, 1999.
37. Cuesta Alcala J.A., Caballero Martinez M.C., Ripa Saldias L. et al.: Therapeutic approach in adrenal melanoma. Review of the literature. Arch. Esp. Urol. 54:685-690, 2001.
38. Mukaiya M., Hirata K., Tarumi K. Et al.: Surgical treatment for recurrent tumors of the primari malignant melanoma of the esophagus: A case report and review of the literature. Hepatogastroenterol. 46:295-298, 1999.
39. McCallum R.W., Connel J.M.C.: Laparoscopic adrenalectomy. Clin. Endocrinol. 55:435-436, 2001.
40. Linos D.A., Stylopoulos N., Boukis M. et al.: Anterior, posterior or laparoscopic approach for the management of the adrenal disease? Am. J. Surg. 173:120-125, 1997.
41. Suzuki K., Ushiyama T., Mugiya S. et al.: Hazards of laparoscopic adrenalectomy in patients with adrenal malignancy. J. Urol. 158:2227, 1997.
42. Elashry O.M., Clayman R.V., Soble J.J. et al.: laparoscopic adrenalectomy for solitary metachronous controlateral adrenal metastasis from renal cell carcinoma. J. Urol. 157:1217-1222, 1997.
43. Winfield H.N., Hamilton B.D., Bravo E.L.: Technique of laparoscopic adrenalectomy. Urol. Clin. North Am. 24:459-465, 1997.